FibroBiologics’ (FBLG) “Buy” Rating Reiterated at D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock.

Several other analysts have also weighed in on the company. EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a research note on Wednesday, September 4th. Maxim Group began coverage on FibroBiologics in a research report on Tuesday, September 24th. They set a “buy” rating and a $12.00 target price for the company. Rodman & Renshaw began coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research note on Wednesday, November 13th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, FibroBiologics has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Price Performance

FBLG opened at $2.31 on Friday. The company has a 50-day simple moving average of $2.68 and a 200 day simple moving average of $3.34. FibroBiologics has a twelve month low of $1.08 and a twelve month high of $55.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new position in shares of FibroBiologics during the third quarter valued at about $32,000. Mercer Global Advisors Inc. ADV bought a new position in FibroBiologics in the 2nd quarter valued at about $51,000. Jane Street Group LLC bought a new position in FibroBiologics in the 3rd quarter valued at about $37,000. Cahaba Wealth Management Inc. acquired a new position in FibroBiologics during the 2nd quarter valued at about $73,000. Finally, Rhumbline Advisers bought a new stake in FibroBiologics during the 2nd quarter worth approximately $115,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.